Maintenance Selinexor Yields Survival Benefit in Advanced or Recurrent Endometrial CancerMarch 23rd 2022
Selinexor demonstrated impressive efficacy in extending progression-free survival among patient with advanced or recurrent endometrial cancer, particularly among patients with wild-type p53 endometrial cancer.
Pembrolizumab Plus Sacituzumab Govitecan Yields Encouraging Antitumor Activity in Metastatic Urothelial CancerFebruary 22nd 2022
Adding sacituzumab govitecan to second-line pembrolizumab garnered promising antitumor activity among patients with checkpoint inhibitor–naïve metastatic urothelial cancer.
Race, Socioeconomic Factors May Impact Survival Outcome in Limited-Stage Small Cell Lung CancerJuly 31st 2021
African American, Asian, and Hispanic patients with limited-stage small cell lung cancer displayed superior survival outcomes compared with White patients, indicating that race might be linked with survival in this disease.
HRD Testing Expands, But Still Lacks Standardization in Ovarian CancerApril 9th 2021
Two tests for homologous recombination deficiency have been FDA approved for patients with ovarian cancer, including myChoice CDx and FoundationOne CDx, and they produce important information that can be used to guide treatment decisions.
Cancer Screening and Diagnoses in Northeast Return to Pre-COVID-19 LevelsMarch 18th 2021
Although cancer screening rates and ensuing diagnoses dropped significantly during the height of the COVID-19 pandemic, testing rates from June 2020 through September 2020 have nearly returned to pre-pandemic levels.
Adjuvant Osimertinib Helps Maintain Health-Related Quality of Life in NSCLCFebruary 6th 2021
Health-related quality of life (HRQoL) was maintained for patients with EGFR-positive non–small cell lung cancer (NSCLC) who received treatment with adjuvant osimertinib (Tagrisso) versus placebo, with no clinically meaningful differences noted between study arms, according to an analysis on patient-reported outcomes (PROs) from the phase 3 ADAURA trial.
BET Inhibitor Shows Promise in Advanced Solid Tumors, Relapsed/Refractory NHLJanuary 11th 2021
The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma, according to the updated results of a phase 1 study (NCT03220347) presented during the 2020 ESMO Virtual Congress.
Acalabrutinib Poses Low Cardiac Risk in CLL, Analysis ShowsDecember 9th 2020
Patients with chronic lymphocytic leukemia (CLL) who received treatment with single-agent acalabrutinib (Calquence) experienced a low incidence of cardiac toxicities leading to treatment discontinuation, according to data from a pooled analysis across 4 clinical trials presented during the 2020 ASH Annual Meeting & Exposition.